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My name is Bob Dinerstein. Im the director of
the clinical program here, as well as director of
the Disability Rights Law Clinic. I'm proud to
have this last panel with Donna Cryer and Amy
Miller. We're going to hear first from Amy, who
is the public policy director of the Personalized
Medicine Coalition, and then we'll hear from
Donna. who is described as a passionate advocate
for personalized medicine and serves on many
boards.
REMARKS F1117RO M AMY MIL,,LER **
Thank you very much for the introduction. I
am Amy Miller, the "passionate" public policy
director of the Personalized Medicine Coalition
(PMC) .As Wayne Rosenkrans said, I guess I'm
the scientist on the panel. I'm a National Institute
of Health (NIH) trained researcher and left
science to do policy and have been in policy since.
I think that I want to start today by saying, I've
never spoken to a group of lavv school students.
I remember the first time I spoke to a group of
medical school students. I w as very nervous, so I
just want to let you know: I don't have a medical
degree, and I don't have a law degree. Keep that
in mind. At PMC, we work to break down barriers
to personalized medicine. Throughout the day,
you've heard different barriers, probably mostly
the regulatory and reimbursement barriers, but
there are other barriers. And I'll get to those in a
minute. But I want to start in a way I don't usually
start, and that's with a story.
At PMC, we had a bit of a wakeup call this week.
We received an email from a woman, who the
executive director of the Personalized Medicine
Coalition has known for a long time. The email
said, "I've written this Op-Ed. Im trying to get
it published. I'm having trouble. Can you help
me out?" And it was about her dying wish-she
was dying of cancer. And Edward Abrahams,
president of the Personalized Medicine Coalition,
said, "Yes, absolutely I'll help you out. I've got
some press connections at these entities. Plus,
we have a newsletter. We'll publish it in the
newsletter no matter what. Let's see what we
can do." She got it published on Forbes' online
blog. It also will be in the next upcoming issue
of Forbes and in our newsletter. She died the day
it was posted online, February 9th. It kind of shook us up at PMC.
We do have consumer advocates, who are part of what we do, but
mostly it is scientists and industry members and some academic
members. It shook us up to have a consumer advocate reach out to
us and say, "This is my dying wish to have my Op-Ed published,"
and then die on the day it was published.
You can probably tell I'm a little emotional about it. Her dying wish
is what we exist to do, which is break down barriers to personalized
medicine and her specific call was for policy makers to break
down barriers like was done for the Orphan Drug Act. So she was
asking Congress and personalized medicine entities to make more
personalized medicine products happen. She had benefited from
one called Ilerceptin, an anti-cancer agent that she says made her
life last a decade longer than it would have otherwise. And she
died at 41, and she said, "I want others to have this gift of a decade
that I had, and I also want there to be more personalized medicine
products, not just this one, Herceptin." You've heard of others like
Gleevec. And there her dying wish is our mission. That was pretty
interesting, so I'm glad Wayne Rosencrans defined personalized
medicine.
When you speak to a group of MI)s, they say, "Oh. we've been
practicing personalized medicine since the dawn of time." And then
we have others who want to debate: Is it personalized medicine?
Is it individualized medicine? Is it personalized health care?
Whatever, we got stuck with personalized medicine, so xve'll go
from there. Personalized medicine is targeting medical treatment
to individualized patient characteristics. That's the definition I
work with. And xwhy do we want to do personalized medicine? I
was talking to my husband about Adrianna, the woman xsho passed
away, her wish, how we can get there faster, how we can shake up
the system and move this along, especially with the split Congress
and especially when it's kind of technical and "niche-y." And he
said, "Well, you know, you talk about medicine today as kind of
random and kind of not scientific. You know, you go to the doctor,
they give you a pill, it doesn't work, you come back, get another pill,
or a newer pill. And you keep doing that." He said, "That's ghastly.
We're going to look back and say that's like bleeding with leeches."
I'm thinking that yes, one hundred years from now, people will
consider that trial and error medicine is like bleeding people with
leeches. It's ghastly; it's illogical; and it's definitely not scientific. So
why do we have this push for personalized medicine? It's because
we want more effective cures sooner rather than later. We xvant
to avoid all of the cost and quality issues that come with trial and
error medicine. We can saxve the health care system money. We
can skyrocket the quality of health care and the quality of patients'
lives. Not to mention, xwe can extend life. So this is whby xxe xxant
pcrsonalizcd medicine. I mentioned that PMC exists to bieak
dostn barricrs. You'vc heard some of them, and I'm just going to
go through my list so you knovs xwhat I focus on. One is business
model barriers IThis is what Adrianna was specifically focusing on,
She was saying drug companies develop drugs. Ihey go through
this drug pipeline, and then they are sold to everybody. Now, for
personalized medicine to work, a drug company needs to partner
with or own a diagnostic unit and develop those together. And then
those two things have to go through the regulatory path at FDA,
which has two separate groups of people that don't particularly like
each other and don't particularly talk all of the time.
Then, when you go to pay for it, usually people pay for a drug
based on what it costs to develop it, plus a little more. But with
diagnostics, you heard Wayne Rosenkrans talk about the stack,
and if you make your test better, you're penalized by getting paid
less. That's if it's even covered at all. As discussed by the fist panel,
sometimes they're not even covered. Well, what does that mean for
personalized medicine when you're trying to develop the drug? You
also have to consider the business model barrier with pharmaceutical
companies being very large and established and having a history of
buying and selling diagnostic units. And then you have diagnostic
companies who tend to be small, entrepreneurial, and to meet up
with "big pharma" to develop a business model, and it's not working
for anyone.
We also have comparative effectiveness research-which Wayne
alluded to briefly as a federal effort to say we have to pay for what
works. And then there's a parenthesis, for the most or for whom,
depending on your slant. And at PMC, xxe advocated successfully for
a comparative effectiveness policy on health care reform that xvould
recognize personalized medicine. And that's in implementation right
now. I'm a little worried that maybe we are going to pretty standard
CER [comparative effectiveness research], what works best for the
most. Are you going to pay for the blue pill or the red pill? It turns
out most people do well on the blue pill, and the blue pill's pretty
cheap. So that's all that we have now is blue pills. But what if the
blue pill does not work for you? Do you not get your extra decade of
life? This is a real question.
We also have some education issues. There's consumer and
physician education. But :we need to think about how to get
personalized medicine into actual practice. For example, warfarin
testing is a business model barrier. You're taking away profits from
hospitals to do a fifty dollar test or maybe a one hundred dollar test.
And doctors are very comfortable with the way warfarin is dosed
right now. Traditionally, age, sex, gender, weight, and things like
that account for 20 percent of initial warfarin response. Having the
genetic indications, that's another 20 percent. So you're doubling
your predictive power. It sounds good to me. It is rat poison. I know
Wayne said that like it vvas a joke, but it's not a joke-that's vvhat it
is; it kills rats.
So, xxe need to think about hoxx to conv ince phy sicians that y es,
it's a little different, it's a little something nexw, but you're doubling
your predictive povvers, so why don't ste use that'? And we need to
educate them a little bit about personalized medicine, Maybe it's
premature, but my grandmother had a lot of trouble with xxarfarin
dosing and xvas on it forever And my aunts are from Louisiana-
not the healthiest group of people. But my aunts vvere talking about
xvhat if we have 'to go on blood thinners with all of these heart
problems and blood pressure. I told them that there's a fancy-pants
new test that can help you get to warfarin dose faster than Mimi, my
grandmother. And they asked, "Is my doctor going to give it to me?"
And I said, "No, you're probably going to ask for it."And the look of
absolute horror on their faces was quite comical. But many patients
are not used to having a dialogue about knowing what works best
for me, and tell me if this is going to work best for me.
Now, the irony is that we have a lot of problems with patients taking
the drugs they're supposed to be taking. I think it's because inside
they know it's kind of trial and error. It's random. There are no real
facts about how this is going to respond for them. There's a lot of
power in saying, "This drug might not work for everyone. But it
will work for you. And ne know this because X'" I know you've
already heard a lot about regulation and reimbursement issues,
but I think the time is right for these issues to be solved. We have
more and more personalized medicine products, a pharmaceutical
industry that is shedding jobs, and a pipeline that's drying up. I feel
like there's a lot of finger-pointing about who is responsible for
the pipeline drying up: pharma points to FDA, and FDA points to
pharma. I think everybody needs to point at science. The science
is moving it towards personalized medicine. I think all of the easy
molecular entities were discovered, and now there are more targeted
therapeutics because we know more about science.
Now we need the regulatory system to catch up. We need the
reimbursement system to catch up. We need the medical care
system to catch up. So. that's what I spend my day doing. Thank you
for inviting me here today. I look forward to your questions.
REMARKS FIROMDONNACYR*
There's a blessing and curse to being the last speaker of the day.
At its best, I could come off looking wise and sage and summarize
this and give you the most poignant take-aways as possible. But, all
my best lines have been taken already. And certainly following Dr.
Miller is always a hard act to follow.
We have a robust personalized medicine practice. Our president
is here today, and he's a pharmacist and has extensive training in
genetic diagnostics and with payers. We have a chief medical officer
who is actually a geneticist by training and did some very early
work in pediatrics and lipid metabolisms and genetic pathways and
things like that. And I don't think that they chose me or made me
come to this because I'm a lawyer and they wanted me to speak to
my people.
I think it's really because I'm the closest to an actual consumer that
there is in the company. The rest of the company is burdened by
knowledge. Clearly Dr. Miller is the scientist on our panel; I am
not. So as today's presentation is "Drugs, DNA, and You," we've
come to the "You" part. low do we get "You" to really enjoy all
of the benefits of personalized medicine that we've heard today?
What does it mean to a consuner to be participating in what we've
recognized to be a robust and growing field? So I think that, first
and foremost, consumers are confused, and my remarks, you
may decide, reflect that confusion, but that means I'm exactly on
point and accurately representing how most consumers feel about
personalized medicine. First of all, the field can't even decide on
a title there is no nomenclature, and as we know as lawyers,
words matter. Do you call it "personalized medicine"? "Genomic-
based medicine"? "Genetics medicine"? "Preventive medicine"?
"Predicative medicine"? "Precision medicine"? "Participatory
nedicine"? "Performance medicine"? Please decide for the
consumer because we need to know.
It was interesting and sort of validating to hear my husband, the
geneticist and chief medical officer of the company (yes, it's a little
nepotism HR trick you can really only do once) remark after reading
in this week's most recent issue of Science a commentary that the
human genome has not, in fact, been sequenced. low many of you
have read in newspapers that the genome has been sequenced and,
thus, everything else will follow in due course? Well, someone
finally said the emperor has no clothes, and the human genoine
has not in fact been sequenced. It's an outline, and there are some
gaps. When my husband, a geneticist, was confused as to that fact
and someone else pointed out what he believed was not true in the
popular media, how do you think consumers feel? If you look at
websites, blogs, industry news reports in the field that everybody
who's spoken to you today is very familiar with, you see energy,
vibrancy, business models and acquisitions, a level of detail, and a
lot of activity. That is not communicated to the average consumer.
They don't knoxw that this is going on. Their aunts in Louisiana are
wondering xvhat this means to them. I think the role of all of us
today is to really figure out wxhat it means to them. So I thought, as a
xvay of summary, to pot together very simple graphics. I nent to Ian
school a long time ago. I think we had PowerPoint, bnt not really.
You certainly didn't get it for moot cour't, so this is my one slide. As
pail of the profession that cieated the filibustei, I could talk for at
least thiree or foui hours on this one slidc, but I won't. I did want to
point out, usually I likc to be part of the first panel because part of
patient advocacy is purting patients first. I'm glad to go last because
I think it better makes the point that so many things need to happen
before we actually get to the consumers actively understanding and
engaging personalized medicine.
So we needindustry innovation; we need a reimbursement framework
that makes sense and values the innovation; we need physician
adoption of these tools: we need a consensus about privacy and
ways that this information will be used; and then we need some type
of standardized education for consumers so that they can integrate
this into their daily lives. All of that needs to happen before we can
really talk about personalized medicine being a reality in practice.
I think amongst all of the definitions consumers or patients think
about it in at least these terms: getting the right drug to the right
patient in the right dose at the right time of disease progression.
As Dr. Rosenkrans on the last panel pointed out, personalized
medicine is perceived particularly from the consumer's standpoint
and much more than just a gene-based therapy. Consumers have
some vague notion if you at least relate it to CSI. but for the most
part, it really is thinking about a personalized service, personalized
information, a tailored diagnosis, a solution-whether it's a pill or
an intervention-that's right for me as an individual, and delivery
of that in a service model that recognizes my humanity and dignity
as a person, as a wxhole person, and not just a list of symptoms or a
collection of data.
I think when consumers and patients talk about personalized
medicine, they're really integrating all of these factors into their
common definition. As you can see from the slide, the primary
hurdles to having personalized medicine in active practice are
primarily about basic knowledge of genes and genomics and trust
in the system. There are ethics issues, privacy issues, and just sort of
personal-cultural issues in a transformation in how we understand
medicine that need to take place as well.
So a little bit on each piece of the framework: industry innovation.
We've had fabulous speakers today on that, but I just wanted to
make the point from a consumer's perspective that it's hard for them
to distinguish between diagnostic tests that are done in the CLIA
[Clinical Laboratory Improvement Amendments] certified lab-
nobody knows what they do, outside of here, those of us who work
in this building know what CLIA is. What are well-validated tests
that are conducted in CLIA-certified labs versus what you might
pick up at CVS? When consumers are discussing it, they're not
really making the fine distinctions between those tests that have
gone tbrough establishing a certain level of clinical utility and
validity and gone through a regulatory process, and those that are
supposed to figure out if y on haxve a naturally happy personality
or y on're supposed to be on the cav eman diet and eat more red
meat. We haxven't really taken the time to explain to consumers
tbe differences between these types of tests, and I think that's very
important. Anotbei important distinction to make for consumers is
tbe diffeience between iisk asscssment and ielatixe and absolute
risk.
Consumers aren't really good with math. (Many of us lawyers aren't
either. That's why we went to law school.) But to be able to distinguish
between tests that affirmatively diagnose a disease versus those that
give information, such as, "You have a two fold increase of risk for
diabetes" is something that needs a fuller explanation to patients
in terms of how they integrate that, how they respond to that, and
how they integrate that into discussions with their doctors. So the
difference between validated diagnostic tests and some home-based
tests, the differences between definitive diagnostic tests and risk
assessment tests are things that are important to consumers. We had
quite a bit of discussion today about companion diagnostics and that
language and targeted therapy, so I xvon't repeat myself.
On the reimbursement framework-others before me have done
a really great job. I think one of the ways that consumers can
participate in that process is to help payers to find the true value
of a test. I've done so as a patient for a test that I'm privileged to
use to guide my care and to guide the clinical decisions that my
doctors make. Ihere is input from multiple stakeholders about what
physicians value in a test, what clinical data they get back, what
other members of the scientific community value in a test, but short
thought is given to quality-of-life issues or other issues that patients
hold dear. My law school experience was shaped by the fact that I
had a liver transplant between first and second year. So you think
second semester recruiting is hard, try doing it from intensive care.
So I use a test, an immune system assay test. It's a blood test
that gives information back to me and my doctor about how my
individual immune system is reacting to the inununosuppressive
drugs that I need to take. The Center for Medicare & Medicaid
Services (CMS), as we've discussed today, didn't want to pay for
the test. Amongst the various arguments about return on investment
and code stacking was my ability to let CM S know the impact that
it would make on patient care. Yes, it was pennywise, pound foolish
for them to not pay a few hundred dollars for a test when they pay
thousands of dollars for somebody to be retransplanted, but what
I was able to get across was the certainty that it gave to me that
my treatment was correct; the faith and the trust that it gave me
that the medication regime that I xvas on was the right one for me;
the ability to know that I could avoid potential rejection, potential
hospitalization, potential cascades of other medications by using
this one test.
And so consumers and patients do have a role in helping to establish
the value proposition, if you will, for personalized medicine,
particularly in the diagnostic area. Dr. Rosenkrans also talked about
phy sician adoption. I'm very luck to be married to one of like ten
geneticists in the country, it seems. There's little genetic training in
medical school to this day, and there are v ery fexv genetic counselors.
It was interesting, as wve discussed, tbat payers have funded a lot of
tbe studies that baxve produced some meaningful effect. For example,
Medco Hlealth Solutions recently made a $5 million commitment to
open a new school of pbairmacy at Faiirleigh Dickinson Unixveirsity
to make sure that pharmacists have tbe background and tiraining to
deal with this new landscape of genomic-based thcrapies.
For consumers, it's vitally important that as much as there are new
direct-to-consumer appeals (and I'm all for having an empowered
and engaged consumer) we need all of our health care professionals
to really be equipped to understand, to interpret, and to use this
new information in guiding our care. So when we talk about
consumers specifically as a segment (not industry, reimbursement,
or physicians--privacy has been addressed by others) we're talking
about what it would take to have consumer understanding. Scientific
and health literacy is low. Numeracy is low. It's very hard to have
consumers deal with and interpret a host of sort of more common,
more accessible health care information or conditions about
cardiovascular disease or breast cancer or things without asking
them to understand pathways and other things. There needs to be
some groundwork laid to be able to discuss genomic medicine or
personalized medicine with consumers.
What's available in the popular media that connects with consumers
are things like, "Oprah got her genes tested." That's great, and so
now we know which tribe in Africa Oprah came from. 'That's what
consumers know about family history. They're not thinking really
about hon family history paired .with new genetic information can
be used to help fill in the gaps and understand and predict their risk
for disease and guide their therapy. I think there's a bit of calibrating
expectations that needs to be done with consumers and patients as
well. While on one hand, there's almost no knowledge of science,
there's a great faith in science and what it can do. And there is a long
way to go in terms of using genomic-based therapies that still has
yet to be realized. The FDA has only recognized thirty biomarkers
as valid to be associated with an approved drug label. so there's a
long way to go, and we need to get consumers on the train now, but
we need to calibrate their expectations of when and how [genomic-
based therapies] can actually impact their care.
One of the most important things to come from an earlier discussion
on consumer engagement and health IT is the idea of informed
consent. Engagement is much more than education, but how you
truly engage consumers in this? And how do you convince them
to consent in, opt in, and fully participate in this process'? I think
that rolling up all of the other points of information, laying the
groundwork now on all of the elements: health, numeracy, this new
layer of genomic information, connecting it to relatable events-
whether it's Oprah or CSI-and involving patients in this can
provide the opportunity for truly informed consent and having
true patient participation in this process. I think the goal should be
consumer participation in personalized medicine.
QUSTIN uestion about safeguards for consumers of health
care. We've heard a lot about the bcneflts of personalized Qcare,
but Dr. DeLoia canler used the example of a forty-eight-year-old
woman nwith breast cancer, and perhaps chemo she wasn't even
40 percent, that based on her genetics they don't thin it vwould be
effcctixve. IHer doctoi thinks that it nouldi be medically necessary.
What vvould be the safeguards?
DONNA RYER:You knon, there is at least a perceived-if not
inherent---tension between personalized medicine and evidence-
based medicine or comparative effectiveness research. I think
though-and Amy can speak to this---the work of the Personalized
Medicine Coalition has really shown that they're not in conflict.
There will always be outliers. I'm an outlier. I think that an
overwhelming number of cases, as ne grow the body of evidence
and become more comfortable with using evidence-based care,
rather than intuitive care, perhaps, is a good description of how it's
been done traditionally. Not only prescribing treatment because
you're in the 40 percent that does well on this drug; but also being
able to explain and have a comfort level with the discussion with
the patient that you're, in fact. not in that 40 percent that does well
on this drug, and we need to try something else or there is currently
nothing else, I think, is probably the more ethical way to go.
AMY MILLER: I think we need to add to it the idea that chemo
isn't aspirin. It's a very nasty drug. When there's a very good chance
this chemo is not going to be helpful to a patient, then you're saving
the patient a very unpleasant experience and the potential health
detriments associated with chemotherapy agents down the line.
And breast cancer treatment is not so black and wx hite-which
chemotherapy agent do we use9 Do we use the standard Tomoxophan,
or do you use an AI? Is there a great chance of reoccurrence or not?
Personalized cancer care is way ahead of many other diseases, and
it's not perfect yet, but again, it is a bit of information the clinician
takes into consideration. If that woman has a crazy family history of
breast cancer, they might be a bit more aggressive than if she's the
only one for example.
ROBERT DINERSTEIN: It's interesting because, when thinking
about personalized medicine, we also have to think about the way in
which individuals process information and predictions in different
ways. I also very much take the point that we're not very good at
understanding math, science, and even why we make decisions the
way we do. A friend of mine just got diagnosed with breast cancer.
In going over some possible treatment alternatives, one choice
presented to her was "if you go this route, you have 25 percent
chance of recovery, and if you go this other route, you'll have 20."
But there was a difference in terms of the side effects. And she told
her friends, I'm not willing to go through this kind of bad treatment
with side effects just for another five percent increment. But some
of her friends, who heard it, said, "My god, why wouldn't you do
anything to increase your odds? I mean going from 20 to 25 percent
that could be the difference." Again, there's no right answer to it.
But what she was saying is based on her own experience about
hon she could piedict shc vould iespond to the side effects. She
thought, "I'm not ready to die, but I really nant to gauge this as to
wvhether this makes sensc foi me." I think that is probably something
that takes a wvhile to get used to from the prov ider end of things
and family members and others to say it's okay to make a different
choice.
AMY MILLER I think providcrs are usced to just throwing
ev erything at it, That's something xve didn't talk about is boxy
prov iders arc incentixvizcd to prov ide. So throw the gamut at each
patient.
QUESTION: Looking at this pyramid, I think that reimbursement
framework is going to be the toughest thing you have to do to get
this pyramid to really work. So what are you doing to try to get the
system to reimburse for personalized medicine?
AMY MILLER: I'm so glad you asked. PMC just published
a compendium of the problems that personalized medicine
technologies face, specifically at CMS. The reason why we did
this is we asked CMS to speak with us at our policy meeting,
which had only forty people. It was a closed meeting-no press,
nobody outside the family. These two doctors came and basically
said some very unscientific things about how all of the data needs
to be collected in the over sixty-four population. Well, that's fine
if genes change once you hit that magic number. But they don't.
There's also an unlevel playing field on how drugs are reimbursed
versus devices or medical laboratory developed tests. They were
just being so crazy and unrealistic. The looks on the people's faces
in the room were quite outstanding, especially people who don't
usually agree. 'They all agreed that this was just ridiculous. PMC
tends to be a consensus-based organization. When we come up with
solutions for policy makers, we like to make sure that they don't
create winners and losers, so we did not go to the next step, which
is offering solutions. It was intentional. BIO, the biotech industry
organization, did take that next step. They interviewed a whole
bunch of experts in the reimbursement paradigm and offered up a
little over six but under twelve solutions. Some are unrealistic and
somxe will absolutely make winners and losers crazy, which means
the lobbyists aren't going to let them happen. But there are a few
two or three-that are feasible and realistic if everybody wants to
really work on the details and get those solutions offered up. So we
are partnering with BIO to work on that. You're absolutely right:
getting the payers to pay is where the buck stops, and it's hard. It's
hard to speak their language; it's hard to come up with solutions
that work for them. I feel like they need to be a partner too. It was
mentioned the data they have control over, and there are some
pseudo-payers nwho are leading the way -the pharmacy benefits
managers (PBMs)-they're starting to do their own research,
improve the quality of the care they provide to patients. I hope that,
by seeing this demonstrated, private payers will say, "You know
what, we do need to partner and come up with some solutions that
are going to work for everyone," because payers will tell you if they
were sitting on this. Theyd say, "If you promise it will work for
people, we'll pay triple or quadruple what we're used to paying for
a diagnostic." But I don't always believe them.
DONNA CRYER: I think you're right. I think it probably is the
hardest nut to crack. It is fascinating to me. The innovation we
have seen-in terms of demonstrating the value and quantifying
the cost savings from use of these technologies-is by the actual
private payers or pseudo payers in the PBM-space or others. And
it is frustrating and rather sad that the government is not following
suit. As far as what consumers can contribute to this, is certainly
heightened interest, a critical mass paying for some of these tests
out of pocket. as they are able. But I remember a story that was
told to us as a sidebar. Agent representatives operate out of the
commissioner's office of the Office of Special House Initiatives,
and it was started really because HIV activists closed the campus
of FDA down. It may come to about that for us to really, truly get
access to personalized therapies. Consumer and patients must
partner with industry in affirming the value of these technologies to
the practice of medicine and making the payers respond.
MODERATOR (Robert Dinerstein): Maybe on that note of
citizen activism would be a good place to end. Please join me in
thanking our panelists.
